ArticleEmerging infectious diseases2019
University-Based Outbreaks of Meningococcal Disease Caused by Serogroup B, United States, 2013-2018.
Article in Emerging infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2020Guideline
- Randomized Trial of 2 Schedules of Meningococcal B Vaccine in Adolescents and Young Adults, CanadaEmerging infectious diseases · 2020Trial
- Burden of Invasive Meningococcal Disease: Evolving Epidemiology and Implications for Prevention Policy.Infectious diseases and therapy · 2026Review
- Meningococcal Outbreaks in Tertiary Education Settings in the United Kingdom: Lessons from the 2026 Kent Cluster for Surveillance, Vaccination Policy, and Institutional Preparedness in Sub-Saharan Africa-A Narrative Review.Infectious disease reports · 2026Review
- Invasive meningococcal B disease: Spatiotemporal cluster identification using finetype data, the Netherlands, 2005-2023.Epidemiology and infection · 2026Article
- Large outbreak of group B invasive meningococcal disease in young adults in South East England, March 2026.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026Article
- Clinical impact and cost-effectiveness of vaccinating infants and adolescents against invasive meningococcal B disease in the Netherlands.BMC medicine · 2026Article
- Meningococcal Disease in Older Adults: Challenges in Diagnosis and Management.Infectious diseases and therapy · 2026Review
- Article
- Need for Invasive Meningococcal Disease Prevention Through Vaccination for Young Children in the Americas.Vaccines · 2025Review
- Prevalence and Risk of Meningococcal Disease or Carriage During Mass Gatherings and Associated Travel: Systematic Review and Meta-Analysis.Tropical medicine and infectious disease · 2025Review
- A Narrative Review of College Meningococcal Vaccination Mandates Across the United States.Vaccines · 2025Review
- Meningococcal Vaccination in the United States: Past, Present, And Future.Paediatric drugs · 2025Review
- Article
- Epidemiology of invasive meningococcal disease, Japan, 2013 to 2023.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2024Article
- Genetic characterization ofFrontiers in cellular and infection microbiology · 2024Article
- Serum bactericidal activity against circulating and reference strains of meningococcal serogroup B in the United States: A review of the strain coverage of meningococcal serogroup B (MenB) vaccines in adolescents and young adults.Human vaccines & immunotherapeutics · 2023Review
- Risk Factors for Serogroup B Meningococcal Disease Among College Students.Open forum infectious diseases · 2023Article
- Meningococcal B Immunisation in Adults and Potential Broader Immunisation Strategies: A Narrative Review.Infectious diseases and therapy · 2023Review
- A National Advisory Committee on Immunization (NACI) update on invasive meningococcal disease (IMD) epidemiology and program-relevant considerations for preventing IMD in individuals at high risk of exposure.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We reviewed university-based outbreaks of meningococcal disease caused by serogroup B and vaccination responses in the United States in the years following serogroup B meningococcal (MenB) vaccine availability. Ten university-based outbreaks occurred in 7 states during 2013-2018, causing a total of 39 cases and 2 deaths. Outbreaks occurred at universities with 3,600-35,000 undergraduates. Outbreak case counts ranged from 2 to 9 cases; outbreak duration ranged from 0 to 376 days. All 10 universities implemented MenB vaccination: 3 primarily used MenB-FHbp and 7 used MenB-4C. Estimated first-dose vaccination coverage ranged from 14% to 98%. In 5 outbreaks, additional cases occurred 6-259 days following MenB vaccination initiation. Although it is difficult to predict outbreak trajectories and evaluate the effects of public health response measures, achieving high MenB vaccination coverage is crucial to help protect at-risk persons during outbreaks of meningococcal disease caused by this serogroup.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.